• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Veradermics Incorporated

    5/15/26 2:02:28 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MANE alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001827635
    VeraDermics, Inc
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Veradermics, Inc
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button not checkedOver Five Years Ago
    Radio button checkedWithin Last Five Years (Specify Year)
    2021
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Veradermics, Inc
    Street Address 1Street Address 2
     470 JAMES STREET
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     NEW HAVEN
     CONNECTICUT
     
     06513
     847-641-0412 




    3. Related Persons

    Last NameFirst NameMiddle Name
    WALDMAN
    REID
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    DURSO
    TIM
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    CARRANO
    DOMINIC
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    GRECO
    MICHAEL
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    NEUMANN
    MARK
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    CORIC
    VLADIMIR
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    CHILDS
    JOHN
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    ENRIGHT
    PATRICK
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    GRANT-KELS
    JANE
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    PANCE
    KATARINA
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    FRIEDMAN
    DAVID
    Street Address 1Street Address 2
     C/O VERADERMICS, INCORPORATED 
     470 JAMES STREET
    CityState/Province/CountryZIP/Postal Code
     NEW HAVEN
     CONNECTICUT
     06513
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-05-01
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox not checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     JEFFERIES LLC
     2347
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    520 MADISON AVENUE
     
    City State/Province/CountryZIP/Postal Code
     NEW YORK
     NEW YORK
     10022
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     

    Recipient Recipient CRD NumberCheckbox not checkedNone
     LEERINK PARTNERS LLC
     39011
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    53 STATE STREET
    40TH FLOOR
    City State/Province/CountryZIP/Postal Code
     BOSTON
     MASSACHUSETTS
     02109
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     

    Recipient Recipient CRD NumberCheckbox not checkedNone
     CITIGROUP GLOBAL MARKETS INC.
     7059
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    388 GREENWICH STREET
    TOWER BUILDING
    City State/Province/CountryZIP/Postal Code
     NEW YORK
     NEW YORK
     10013
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     

    Recipient Recipient CRD NumberCheckbox not checkedNone
     CANTOR FITZGERALD & CO.
     134
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    110 EAST 59TH STREET
    4TH FLOOR
    City State/Province/CountryZIP/Postal Code
     NEW YORK
     NEW YORK
     10022
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     

    Recipient Recipient CRD NumberCheckbox not checkedNone
     LIFESCI CAPITAL
     168404
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    1700 BROADWAY
    40TH FLOOR
    City State/Province/CountryZIP/Postal Code
     NEW YORK
     NEW YORK
     10019
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     

    Recipient Recipient CRD NumberCheckbox not checkedNone
     NEEDHAM & COMPANY, LLC
     16360
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    250 PARK AVENUE
    10TH FLOOR
    City State/Province/CountryZIP/Postal Code
     NEW YORK
     NEW YORK
     10177
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    29999997
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    29999997
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    2
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    1800000
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Veradermics, IncREID WALDMANREID WALDMANCHIEF EXECUTIVE OFFICER2026-05-14




    Get the next $MANE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MANE

    DatePrice TargetRatingAnalyst
    7/15/2026$170.00Buy
    B. Riley Securities
    6/2/2026$136.00Buy
    Needham
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$85.00Buy
    Citigroup
    3/2/2026$75.00Buy
    Jefferies
    3/2/2026$75.00Outperform
    Leerink Partners
    More analyst ratings

    $MANE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

    4/A - Veradermics, Inc (0001827635) (Issuer)

    2/27/26 4:44:06 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/9/26 6:28:51 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/5/26 7:04:25 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    SEC Filings

    View All

    Veradermics Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Veradermics, Inc (0001827635) (Filer)

    7/15/26 8:54:36 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Veradermics Incorporated

    SCHEDULE 13G/A - Veradermics, Inc (0001827635) (Subject)

    5/15/26 5:48:36 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Veradermics Incorporated

    D - Veradermics, Inc (0001827635) (Filer)

    5/15/26 2:02:28 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

    Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral min

    7/17/26 7:30:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with

    7/15/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

    Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab

    7/14/26 6:54:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Veradermics with a new price target

    B. Riley Securities initiated coverage of Veradermics with a rating of Buy and set a new price target of $170.00

    7/15/26 8:53:05 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Veradermics with a new price target

    Needham initiated coverage of Veradermics with a rating of Buy and set a new price target of $136.00

    6/2/26 8:39:26 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Veradermics

    Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight

    3/2/26 9:08:57 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Suvretta Capital Management, Llc

    4 - Veradermics, Inc (0001827635) (Issuer)

    5/5/26 9:37:59 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Seven Fleet Capital Management Lp claimed ownership of 80,000 shares (SEC Form 3)

    3 - Veradermics, Inc (0001827635) (Issuer)

    5/5/26 7:42:22 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Childs John W bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

    4/A - Veradermics, Inc (0001827635) (Issuer)

    2/27/26 4:44:06 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Financials

    Live finance-specific insights

    View All

    Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with

    7/15/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

    Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab

    7/14/26 6:54:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss

    VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient

    4/27/26 7:00:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care